CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today that the trading symbol for its Class A
common stock will revert from BPURD to BPUR at the open of the market on
Wednesday, October 31, 2007. Outstanding warrants that trade on the OTCBB
will revert to the following ticker symbols: BPREW reverting to BPURW;
BPREZ reverting to BPURZ; and BPREL reverting to BPURL.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. Biopure has applied
in the United Kingdom for regulatory approval of a proposed orthopedic
surgical anemia indication. The company is developing Hemopure for several
other indications and is supporting the U.S. Navy's government-funded
efforts to develop a potential out-of-hospital trauma indication. Biopure's
veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or
HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and
Drug Administration and the European Commission, is indicated for the
treatment of anemia in dogs. Biopure has sold approximately 186,000 units
of Oxyglobin, which have been used to treat an estimated 100,000 animals.
Statements in this release that are not strictly historical are
forward- looking statements, including those statements implying that any
planned clinical trial will be carried out or that study results will be as
desired, statements related to the timing and response of the MHRA review
and any statements that might imply that Hemopure may receive marketing
approval in additional jurisdictions or for additional indications. Actual
results and their timing may differ materially from those projected in
these forward- looking statements due to risks and uncertainties. These
risks include, without limitation, uncertainties regarding the company's
financial position, including its limited cash resources and need to raise
additional capital to pursue these initiatives, unexpected costs and
expenses, delays and adverse determinations by regulatory authorities,
unanticipated problems with the product's commercial use, whether or not
product related, and with product distributors, sales agents or other third
parties, delays in or unpredictable outcomes of clinical trials, and the
other factors identified under the heading "Risk Factors" in the company's
quarterly report on Form 10-Q filed on September 14, 2007, which can be
accessed in the EDGAR database at the U.S. Securities and Exchange
Commission's (SEC) website, http://www.sec.gov. The company undertakes no
obligation to release publicly the results of any revisions to these
forward-looking statements to reflect events or circumstances arising after
the date hereof. A full discussion of the company's operations and
financial condition can be found in the company's filings with the SEC.
The content of this release does not necessarily reflect the position
or the policy of the U.S. Government or the Department of Defense, and no
official endorsement should be inferred.
Contact: Tiana Gorham Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Tiana Gorham of Biopure Corporation,
+1-617-234-6826, IR@biopure.com; or Herb Lanzet (Investors) of
H.L. Lanzet Inc., +1-212-888-4570, lanzet@aol.com
|
